Efficacy and Safety of Ensitrelvir for Asymptomatic or Mild COVID-19: An Exploratory ...
A phase 2b/3 trial evaluated ensitrelvir's efficacy and safety in asymptomatic SARS-CoV-2 and mild COVID-19 patients. Conducted in Japan, South Korea, and Vietnam, participants were randomized to ensitrelvir 125-mg, 250-mg, or placebo groups. Ensitrelvir showed potential in reducing COVID-19 symptom development/worsening and demonstrated antiviral efficacy with mostly mild to moderate adverse events.
Reference News
A phase 2b/3 trial evaluated ensitrelvir's efficacy and safety in asymptomatic SARS-CoV-2 and mild COVID-19 patients. Conducted in Japan, South Korea, and Vietnam, participants were randomized to ensitrelvir 125-mg, 250-mg, or placebo groups. Ensitrelvir showed potential in reducing COVID-19 symptom development/worsening and demonstrated antiviral efficacy with mostly mild to moderate adverse events.